The user experienced significant hair loss due to health issues and has only taken vitamins for recovery. They are seeking advice on regrowth progress after two months.
The user is seeking advice on the best treatment for male pattern baldness, diffuse thinning, and retrograde alopecia, comparing the effectiveness of finasteride, RU58841, and dutasteride, and considering whether to add minoxidil or switch to dutasteride or combine treatments. They are currently on finasteride and are contemplating if adding RU58841 or switching to dutasteride is better, and also asking about the comparison between pyrilutamide and RU58841.
Hair loss treatments like Minoxidil, finasteride, and RU58841, focusing on their effectiveness and side effects. It also highlights the disparity in medical research funding between hair loss and conditions like endometriosis.
A 34-year-old man started using oral finasteride and topical minoxidil in late August for hair regrowth and noticed significant progress. He shared his results and expressed gratitude, while also mourning his father's recent passing.
The conversation discusses alternative and unorthodox hair loss treatments, including RU58841, nandrolone, and dianabol, as well as theoretical approaches involving high doses of estrogen and selective estrogen receptor modulators. These methods are considered extreme and potentially harmful but are explored for those unable to tolerate traditional 5-alpha reductase inhibitors.
KY19382, a promising compound for hair loss, is not widely discussed or used. One user is currently testing it and plans to share results in a few weeks.
The user experienced hair thinning with dandruff and itchiness but not complete baldness, and found relief using dermarolling and castor oil. They did not use minoxidil or finasteride and discussed the potential impact of lifestyle choices on hair loss.
The conversation discusses using shou wu chih or fo-ti/he shou wu for hair loss, with OP noticing stiffer beard and body hair. A user warns about potential liver damage from fo-ti and questions the effectiveness of alternative medicine.
The conversation discusses struggles with diffuse thinning and hair loss treatments, including the use of dutasteride, minoxidil, and finasteride, with limited success. The original poster regrets having a hair transplant at 21 due to weak donor hair and ongoing thinning.
The conversation discusses personal experiences with hair loss and highlights the potential impact of anemia and nutrient deficiencies on hair health. Treatments mentioned include changing shampoo/conditioner, taking MSM, collagen, hyaluronic acid, astaxanthin, B12, folate, and bovine blood capsules.
The post and conversation are about a user claiming to be 137 years old with a full head of hair. Specific treatments mentioned include dutasteride, RU58841, and minoxidil.
The conversation discusses concerns about body dysmorphia related to hair loss, with some users expressing frustration over posts claiming treatments like finasteride and dutasteride are ineffective or harmful despite minimal hair loss. It emphasizes the importance of early treatment with medications like finasteride and minoxidil for those experiencing hair loss.
Hair loss treatments, with users discussing their experiences with both RU58841 and Pyrilutamide, noting that the latter has only recently become available but may yield better results in the long term.
Long-term RU58841 users discuss its effectiveness, with some finding it not worth the cost compared to other treatments like Dutasteride and Minoxidil. One user experienced side effects from a chemical company product, while another is regrowing hair after stopping RU58841.
The user has been losing hair for over two years despite taking dutasteride and RU58841, even increasing dutasteride to 2.5mg. They are questioning if their hair loss could be due to telogen effluvium instead.
GT20026 is discussed as a potential treatment for hair loss that targets androgen receptors without affecting hormone levels, but it may not promote significant regrowth. It is expected to be available by 2028, with other treatments like Breezula and Clascoterone also mentioned.
Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.
Minoxidil and finasteride are being considered for hair loss due to seborrheic dermatitis and male pattern baldness. The user is also using ketoconazole and zinc pyrithione shampoo.
PP405 is considered a potential new treatment for hair loss, compared to finasteride and minoxidil. There is skepticism about its effectiveness in humans, with anticipation for more information from an upcoming conference.
Pyrilutamide, a potential hair loss treatment that has recently been released for sale, and is thought to have similar efficacy to Dutasteride without side effects. It was discussed in terms of its effectiveness compared to Finasteride, its use by females, and whether it can be safely mixed with RU58841.
The conversation is about the importance of acting quickly against hair loss. The user shares their experience with androgenic alopecia and mentions using finasteride without improvement.
User experienced hair loss after weight lifting, had a successful hair transplant, but later faced significant thinning. Current treatment includes finasteride, minoxidil, dermal rolling, and supplements.
A user is experiencing rapid hair loss and has been diagnosed with telogen effluvium by multiple dermatologists, but doubts the diagnosis due to the severity and speed of the hair loss. They are considering various treatments like spironolactone, estradiol, and possibly finasteride, while also exploring the possibility of hormonal imbalances or autoimmune issues.
A young person regrets not starting hair loss treatments like minoxidil and finasteride earlier, leading to significant balding by age 19. They discuss the importance of early intervention and the impact of societal perceptions on those experiencing hair loss.
RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.
An 18-year-old is using a high-dose hair loss treatment regimen including finasteride, minoxidil, dutasteride, and plans to add RU58841 and bimatoprost, despite warnings from others about the risks. The user is determined to reverse hair loss but acknowledges the potential dangers and does not recommend others follow their approach.
A user regrets not starting finasteride earlier for hair loss, noticing significant crown thinning by age 30. They have started using finasteride and are considering minoxidil for better hair regrowth.
The conversation is a humorous discussion about hair loss, with users expressing envy towards an ancient figure who still has a full head of hair. No specific treatments are mentioned.
A user's decision to shave their head after experiencing hair loss since the age of 17, and discussion around the potential use of Fin for treating hair loss.